A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Drotrecogin Alfa (Activated) Administered as a Continuous 96-hr Infusion to Adult Patients With Septic Shock

The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated)
treatment provides significant mortality reduction improvement in patients with septic shock
compared with placebo treatment in patients receiving the current standard of care for septic
shock. This study will also assess the effectiveness of drotrecogin alfa (activated) in
reducing 28-day mortality in patients with septic shock and concomitant severe protein C
deficiency.